Skip to main content
Journal cover image

Management of recurrent melanoma of the extremity.

Publication ,  Journal Article
Shingleton, WW; Seigler, HF; Stocks, LH; Downs, RW
Published in: Cancer
March 1975

Two forms of therapy employed for treatment of patients with recurrent melanoma limited to the extremity, and carried out during different intervals of time, are presented. Perfusion of the involved extremity with phenylalanine mustard has resulted in a 5-year survival rate of 28% of 43 patients. A second group of 25 patients has been treated by a four-stage immunotherapy program consisting of sensitization with intradermal BCG, followed in 6 weeks by intra tumor injection of BCG. A third stage involved the activation of the patients's lymphocytes, after removal by a blood cell separator, incubated in vitro with irradiated neuraminidase-treated melanoma cells and reintroduced into the patient either by subcutaneous or intratumor injection. The fourth stage of immunotherapy involves injection of an inoculum of irradiated neuraminidase-treated autochothonous tumor cells plus BCG injected intratumorally or subcutaneously. Sixteen of 24 patients receiving immunotherapy treatment program have experienced arrest of their disease lasting from 5 to 42 months.

Duke Scholars

Published In

Cancer

DOI

ISSN

0008-543X

Publication Date

March 1975

Volume

35

Issue

3

Start / End Page

574 / 579

Location

United States

Related Subject Headings

  • Transplantation, Autologous
  • Skin Neoplasms
  • Perfusion
  • Oncology & Carcinogenesis
  • Nitrogen Mustard Compounds
  • Neuraminidase
  • Neoplasm Recurrence, Local
  • Middle Aged
  • Melphalan
  • Melanoma
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Shingleton, W. W., Seigler, H. F., Stocks, L. H., & Downs, R. W. (1975). Management of recurrent melanoma of the extremity. Cancer, 35(3), 574–579. https://doi.org/10.1002/1097-0142(197503)35:3<574::aid-cncr2820350303>3.0.co;2-5
Shingleton, W. W., H. F. Seigler, L. H. Stocks, and R. W. Downs. “Management of recurrent melanoma of the extremity.Cancer 35, no. 3 (March 1975): 574–79. https://doi.org/10.1002/1097-0142(197503)35:3<574::aid-cncr2820350303>3.0.co;2-5.
Shingleton WW, Seigler HF, Stocks LH, Downs RW. Management of recurrent melanoma of the extremity. Cancer. 1975 Mar;35(3):574–9.
Shingleton, W. W., et al. “Management of recurrent melanoma of the extremity.Cancer, vol. 35, no. 3, Mar. 1975, pp. 574–79. Pubmed, doi:10.1002/1097-0142(197503)35:3<574::aid-cncr2820350303>3.0.co;2-5.
Shingleton WW, Seigler HF, Stocks LH, Downs RW. Management of recurrent melanoma of the extremity. Cancer. 1975 Mar;35(3):574–579.
Journal cover image

Published In

Cancer

DOI

ISSN

0008-543X

Publication Date

March 1975

Volume

35

Issue

3

Start / End Page

574 / 579

Location

United States

Related Subject Headings

  • Transplantation, Autologous
  • Skin Neoplasms
  • Perfusion
  • Oncology & Carcinogenesis
  • Nitrogen Mustard Compounds
  • Neuraminidase
  • Neoplasm Recurrence, Local
  • Middle Aged
  • Melphalan
  • Melanoma